TrialJournal for immunotherapy of cancer2017

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials.

Howard L Kaufman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.